DNA Vaccines: Technologies and Global Markets
December 03, 2009
Wellesley, Mass. – According to a new technical market research report, DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS (BIO067A) from BCC Research (www.bccresearch.com), the global market for DNA vaccines is an estimated $193.2 million in 2009, but is expected to increase to more than $2.7 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 69.5%.
The largest segment in the market currently, research tools, is expected to increase at a 5-year CAGR of 12.6%, increasing from $91.7 million in 2009 to $165.7 million in 2014.
The second-largest segment, animal health, is expected to reach $261.4 million in 2014. The market in 2009 is estimated at $78 million. Thus, the 5-year CAGR is projected to be 27.4%.
The segment projected to see the largest growth from 2009 to 2014 is human health. It is expected to increase from an estimated $23.5 million in 2009 to nearly $2.3 billion in 2014, for a 5-year CAGR of 149.6%.
SUMMARY FIGURE
GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014
($ MILLIONS)
To Contact us, click here 
Source: BCC Research
The vaccines market, once a backwater of the pharmaceutical industry, is now considered to be an attractive growth opportunity. DNA vaccines make up an emerging vaccine platform within this changing paradigm. They target a wide range of traditional pharmaceutical markets, such as cancers and allergies, as well as infectious diseases.
New biotechnologies and nanotechnologies are driving DNA vaccine development. Particularly important to DNA vaccines reaching their potential are emerging delivery technologies such as electroporation, innovative vaccine formats such as DNA prime-adenovector boost, and novel molecular adjuvant technologies. These technologies are providing the means for achieving higher efficacy in humans that is required for commercialization of DNA vaccines.
These vaccines have already made significant progress to date. There are three approved DNA vaccines for animal health applications and nearly 100 clinical trials underway in humans for a wide range of diseases. There is a deep pipeline of preclinical projects.
This report will serve as a useful industry guide for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefense companies; as well as for suppliers of genetic tools, synthetic genes and vaccine adjuvants. It will also be of interest to professionals within the regulatory agencies to understand the scope and pace of DNA vaccine technologies as they move from clinical trials into the market.
DNA Vaccines: Technologies and Global Markets( BIO067A )
Publish Date: Sep 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
DNA Vaccines: Technologies and Global Markets
Customize This Report More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum